Immix Biopharma, Inc. Common Stock (IMMX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMMX trades at $9.49 with a market cap of $489.16M and a P/E ratio of -9.91. IMMX moved +1.02% today. Year to date, IMMX is +75.29%; over the trailing twelve months it is +323.70%. Its 52-week range spans $1.26 to $11.61. Analyst consensus is strong buy with an average price target of $18.25. Rallies surfaces IMMX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own IMMX include Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immix Biopharma, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $9.49 |
| Market Cap | $489.16M |
| P/E Ratio | -9.91 |
| EPS | $-0.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.61 |
| 52-Week Low | $1.26 |
| Volume | 448.53K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-29.44M |
| Gross Margin | 0.00% |
4 analysts cover IMMX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.25.